Q2 2022 EPS Estimates for Intercept Pharmaceuticals, Inc. Lowered by Analyst (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating) – Stock analysts at Oppenheimer dropped their Q2 2022 EPS estimates for Intercept Pharmaceuticals in a research report issued on Sunday, May 8th. Oppenheimer analyst J. Olson now forecasts that the biopharmaceutical company will post earnings per share of ($0.70) for the quarter, down from their previous estimate of ($0.56). Oppenheimer also issued estimates for Intercept Pharmaceuticals’ Q3 2022 earnings at ($0.21) EPS, Q4 2022 earnings at ($0.80) EPS, FY2022 earnings at ($2.30) EPS, FY2024 earnings at ($5.07) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at $0.53 EPS.

Intercept Pharmaceuticals (NASDAQ:ICPTGet Rating) last posted its earnings results on Friday, May 6th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.31. During the same period in the previous year, the business posted ($1.22) EPS.

A number of other research analysts have also weighed in on the company. SVB Leerink reduced their target price on Intercept Pharmaceuticals from $30.00 to $27.00 and set a “market perform” rating for the company in a report on Thursday, March 3rd. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $14.00 target price for the company in a report on Monday, March 7th. StockNews.com initiated coverage on shares of Intercept Pharmaceuticals in a research report on Thursday, March 31st. They issued a “buy” rating on the stock. Needham & Company LLC decreased their price objective on shares of Intercept Pharmaceuticals from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 3rd. Finally, Canaccord Genuity Group decreased their price objective on shares of Intercept Pharmaceuticals from $31.00 to $29.00 and set a “hold” rating on the stock in a research report on Tuesday, March 8th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Intercept Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $27.23.

ICPT stock opened at $18.77 on Wednesday. The firm has a market capitalization of $557.71 million, a PE ratio of -8.34 and a beta of 1.27. Intercept Pharmaceuticals has a twelve month low of $11.60 and a twelve month high of $22.36. The stock has a 50-day simple moving average of $16.39 and a two-hundred day simple moving average of $16.44.

A number of hedge funds and other institutional investors have recently modified their holdings of ICPT. Adage Capital Partners GP L.L.C. bought a new position in Intercept Pharmaceuticals during the fourth quarter valued at approximately $20,086,000. Point72 Asset Management L.P. bought a new position in Intercept Pharmaceuticals during the third quarter valued at approximately $10,376,000. Millennium Management LLC purchased a new stake in shares of Intercept Pharmaceuticals during the fourth quarter valued at approximately $9,117,000. Eventide Asset Management LLC purchased a new stake in shares of Intercept Pharmaceuticals during the fourth quarter valued at approximately $5,334,000. Finally, Balyasny Asset Management LLC purchased a new stake in shares of Intercept Pharmaceuticals during the third quarter valued at approximately $3,575,000. Institutional investors and hedge funds own 83.44% of the company’s stock.

About Intercept Pharmaceuticals (Get Rating)

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.

See Also

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.